Market Performance - A-shares opened higher with the Shanghai Composite Index rising by 1.18% to 3996.94 points, Shenzhen Component up 1.51%, and ChiNext Index up 1.98%[1] - Hong Kong's Hang Seng Index closed up 1.05% at 26433.7 points, with the Hang Seng Tech Index increasing by 1.83% and the Hang Seng China Enterprises Index up 1.1%[1] - The total market turnover reached 2670.772 million HKD[1] Economic Developments - The People's Bank of China announced the resumption of government bond trading operations, with analysts expecting a quick restart to stabilize bond supply and demand[1][12] - The EU and China are set to discuss temporary allowances for semiconductor exports, particularly concerning Nexperia's operations in China[12] Sector Highlights - Lithium battery and semiconductor sectors led the gains in the A-share market[1] - The semiconductor sector showed a strong rebound, while non-ferrous metals also strengthened[1] International Market Trends - US stock indices all closed higher, with the Dow Jones up 0.71%, S&P 500 up 1.23%, and Nasdaq up 1.86%[1] - European stock indices also saw slight increases, reflecting a positive sentiment in global markets[1]

Policy Developments - The National Medical Products Administration (NMPA) held a meeting on May 28 to discuss the "Clearing Source" action in the drug distribution sector, emphasizing strict enforcement of regulations and collaboration across departments to ensure drug quality and safety [2]. Drug and Device Approvals - Novartis announced on May 28 that its anti-VEGF monoclonal antibody, Brolucizumab, has been approved by the NMPA for the treatment of diabetic macular edema (DME), allowing for injections every three months after the loading phase [4]. - On the same day, the NMPA accepted the new drug application (NDA) for Rocbrutinib, a fourth-generation BTK inhibitor developed by LuPeng Pharmaceutical, which is intended for adult patients with mantle cell lymphoma (MCL) who have previously received BTK inhibitor treatment [5]. Capital Market Activities - Zhenmai Bio completed a C+ round financing of 280 million yuan on May 28, with participation from multiple investors, aiming to focus on "commercial ecosystem construction" and "global expansion" [7]. Industry Events - On May 27, Anmai Bio announced a global licensing agreement with Juri Biosciences for the development of KLK2 and CD3 T-cell engaging molecules for metastatic prostate cancer, with potential payments up to 210 million USD [9]. - Eli Lilly announced on May 27 that it will acquire SiteOne Therapeutics, a startup focused on developing sodium channel inhibitors for pain management, with a total deal value of up to 1 billion USD [10]. Regulatory and Compliance Issues - ST Longjin announced on May 28 that it received a decision from the Shenzhen Stock Exchange to terminate its stock listing, effective June 27, 2025, due to non-compliance with listing rules [12]. - ST Jiyuan's stock will be delisted on May 29, 2025, after failing to maintain a closing price above 1 yuan for 20 consecutive trading days [14]. - ST Suwu reported on May 28 that it is under investigation by the China Securities Regulatory Commission (CSRC) for information disclosure violations, but its daily operations remain normal [15]. - Jiaying Pharmaceutical announced on May 28 that it is under investigation by the CSRC for suspected information disclosure violations and will cooperate with the regulatory body [16].